56547-82-1

Basic information

• Product Name: 2-CYCLOHEXYL-5-METHYL-2H-PYRAZOL-3-YLAMINE
• Synonyms: 2-CYCLOHEXYL-5-METHYL-2H-PYRAZOL-3-YLAMINE;1-CYCLOHEXYL-3-METHYL-1H-PYRAZOL-5-AMINE;1-cyclohexyl-3-methyl-1H-pyrazol-5-amine(SALTDATA: FREE);1-Cyclohexyl-3-methyl-1H-pyrazol-5-amine AldrichCPR
• CAS NO: 56547-82-1
• Molecular Formula: C₁₀H₁₇N₃
• Molecular Weight: 179.26
• Mol File: 56547-82-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 336.3°C at 760 mmHg
• Flash Point: 157.2°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 0.000113mmHg at 25°C
• Refractive Index: 1.624
• CAS DataBase Reference: 2-CYCLOHEXYL-5-METHYL-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CYCLOHEXYL-5-METHYL-2H-PYRAZOL-3-YLAMINE(56547-82-1)
• EPA Substance Registry System: 2-CYCLOHEXYL-5-METHYL-2H-PYRAZOL-3-YLAMINE(56547-82-1)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 56547-82-1(Hazardous Substances Data)

Usage

General Description

2-Cyclohexyl-5-methyl-2H-pyrazol-3-ylamine is a chemical compound with the molecular formula C11H18N4. It is a pyrazole derivative and a member of the amine class of organic compounds. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has the potential to act as a ligand in coordination chemistry and as a reagent in organic synthesis. 2-Cyclohexyl-5-methyl-2H-pyrazol-3-ylamine may also have potential biological activity and is being studied for its potential use in the treatment of certain health conditions.

InChI:InChI=1/C10H17N3/c1-8-7-10(11)13(12-8)9-5-3-2-4-6-9/h7,9H,2-6,11H2,1H3

Upstream product

• 1118-61-2 3-Aminocrotononitrile 
• 6498-34-6 cyclohexylhydrazine 
• 24214-73-1 cyclohexylhydrazine hydrochloride 
• 108-94-1 cyclohexanone 
• 60295-21-8 N'-cyclohexyl-hydrazine carboxylic acid tert-butyl ester 
• 60295-11-6 tert-butyl 2-cyclohexylidenehydrazine-1-carboxylate 
• 2469-99-0 Cyanoaceton 

Downstream Products

• 2126040-21-7 C₁₈H₂₁ClFN₃O 

Relevant articles and documents

Discovery, synthesis and biological characterization of a series of: N -(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1 H -pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of N-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers as G protein-gated inwardly-rectifying potassium (GIRK) channel activators. From our previous lead optimization efforts, we have identified a new ether-based scaffold and paired this with a novel sulfone-based head group to identify a potent and selective GIRK1/2 activator. In addition, we evaluated the compounds in tier 1 DMPK assays and have identified compounds that display nanomolar potency as GIRK1/2 activators with improved metabolic stability over the prototypical urea-based compounds. This journal is

HDAC inhibitor and preparation method and application thereof

The present invention discloses a compound represented by a formula I, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The invention further relates to a pharmaceutical composition containing the compound shown in the formula I and application of the compound in preparation of HDAC inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for treating cell proliferation diseases, autoimmune diseases, inflammation, neurodegenerative diseases or viral diseases.

Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators

The G protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) are a family of inward-rectifying potassium channels, and there is significant evidence supporting the roles of GIRKs in a number of physiological processes and as potential targets for numerous indications. Previously reported urea containing molecules as GIRK1/2 preferring activators have had significant pharmacokinetic (PK) liabilities. Here we report a novel series of 1H-pyrazolo-5-yl-2-phenylacetamides in an effort to improve upon the PK properties. This series of compounds display nanomolar potency as GIRK1/2 activators with improved brain distribution (rodent Kp > 0.6).